<--- Back to Details
First PageDocument Content
Health / Medicine / Breakthrough therapy / Specialty drugs / Gilead Sciences / Healthcare-associated infections / Cyclopropanes / Sofosbuvir / Ledipasvir / National Institute for Health and Care Excellence / Hepatitis / National Health Service
Date: 2016-07-02 14:50:25
Health
Medicine
Breakthrough therapy
Specialty drugs
Gilead Sciences
Healthcare-associated infections
Cyclopropanes
Sofosbuvir
Ledipasvir
National Institute for Health and Care Excellence
Hepatitis
National Health Service

Microsoft Word - GILEAD BRIEFING

Add to Reading List

Source URL: www.ukts.org

Download Document from Source Website

File Size: 102,77 KB

Share Document on Facebook

Similar Documents

Health care / Specialty drugs / Health / Clinical pharmacology / Medical prescription / Patient safety / Pharmaceutical sciences / Express Scripts / Pharmacy / Pharmacist / Pharmacies / Pharmacy benefit management

California Schools VEBA Important Benefit Update Attention Member IMPORTANT: If you have not received your Welcome Kit with your ID cards, please

DocID: 1rr76 - View Document

Gilead Sciences / Chemistry / HIV/AIDS / Medicine / Organofluorides / Specialty drugs / Prodrugs / Prevention of HIV/AIDS / AIDS Healthcare Foundation / Tenofovir alafenamide / Tenofovir disoproxil / Fixed-dose combination

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

DocID: 1rqYi - View Document

Pharmaceutical sciences / Pharmacology / Health care / Pharmaceuticals policy / Pharmaceutical industry / Pharmacy / Drugs / Clinical pharmacology / Medicare Part D / Specialty drugs / Prescription drug / Medicare

February 2016 Rx Price Watch Report

DocID: 1rosR - View Document

Specialty drugs / Monopoly / Biotechnology / Business / Intellectual property law / Law / Patent law / Propionates / Sofosbuvir / Patent infringement / Dehns / Patent attorney

présenteit - mediA - phA rmA

DocID: 1riP0 - View Document

Business / Economy / Biotechnology / American brands / Specialty drugs / CAC 40 / Sanofi / Biosimilar / Biopharmaceutical / Janssen Biotech / Fine chemical / Johnson & Johnson

PDF Document

DocID: 1ri6p - View Document